en · de · es · fr · pt
semax-notes.peptides6579.com › News › Semax Peptide Background And Identity — Reference Sheet

Semax Peptide Background And Identity — Reference Sheet

By Editorial Desk · published 2025-10-10 · last reviewed 2025-11-04 · News

The short version of freeze-thaw fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-11-04. Anything still debated is marked as such rather than presented as settled.

Semax Peptide Background and Identity

Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.

Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.

Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.

Mechanism and Research Context

Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.

The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.

Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.

Semax at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptide (ACTH fragment analog)Not a steroid; does not belong to the melanocortin agonist drugs by marketing category
Molecular formulaC37H51N9O10S (commonly cited)Reported values vary slightly with salt and counter-ion content
AppearanceWhite to off-white lyophilized powderA single batch may appear as a loose cake or fluffy solid
SolubilityFreely soluble in water and aqueous bufferStock solutions are usually prepared in sterile water or saline
Typical storage−20 °C or below, desiccated and protected from lightSeal opened vials promptly to limit moisture uptake

Chemical Identity and Research Background

Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.

Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.

Related pages on this site

Handling, Storage, and Analytical Methods

Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.

Solid material is normally kept at minus 20 degrees Celsius in a sealed, desiccated container. Reconstituted solutions are less stable and are usually divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of activity. Light exposure is minimized by using amber glassware or foil wrapping. Published stability data for this peptide are sparse, so recommended storage conditions rest mainly on general practice for short synthetic peptides rather than on dedicated study.

Background and Development

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.

Further detail

Atkins, P.W., Overton, T., Rourke, J., Weller, M. and Armstrong, F. Shriver and Atkins Inorganic Chemistry (4th ed.) 2006 (Oxford University Press) ISBN 0-19-926463-5 Chang, Raymond. Chemistry 6th ed. Boston, Massachusetts: James M. Smith, 1998. ISBN 0-07-115221-0 Clayden, Jonathan; Greeves, Nick; Warren, Stuart; Wothers, Peter (2001). Organic Chemistry (1st ed.). Oxford University Press. ISBN 978-0-19-850346-0. Tucker, William (2024). Chemistry: Energy, Matter, and Change. CRC Press. ISBN 9781003479338. Advanced undergraduate-level or graduate textbooks

== Activity == LepA exhibits uncoupled GTPase activity. This activity is stimulated by the ribosome to the same extent as the activity of EF-G, which is known to have the strongest ribosome-dependent GTPase activity among all characterized G proteins involved in translation. Conversely, uncoupled GTPase activity occurs when the ribosome stimulation of GTP cleavage is not directly dependent on protein synthesis. In the presence of GTP, LepA works catalytically. On the other hand, in the presence of the nonhydrolysable GTP – GDPNP – the LepA action becomes stoichiometric, saturating at about one molecule per 70S ribosomes. This data demonstrates that GTP cleavage is required for dissociation of LepA from the ribosome, which is demonstrative of a typical G protein. At low concentrations of LepA (less than or equal to 3 molecules per 70S ribosome), LepA specifically recognizes incorrectly translocated ribosomes, back-translocates them, and thus allows EF-G to have a second chance to catalyze the correct translocation reaction. At high concentrations (about 1 molecule per 70S ribosome), LepA loses its specificity and back-translocates every POST ribosome. This places the translational machinery in a nonreproductive mode. This explains the toxicity of LepA when it is found in a cell in high concentrations. Hence, at low concentrations LepA significantly improves the yield and activity of synthesized proteins; however, at high concentrations LepA is toxic to cells. Additionally, LepA has an effect on peptide bond formation.

=== 1.4 === DisplayPort version 1.4 was published 1 March 2016. No new transmission modes are defined, so HBR3 (32.4 Gbit/s) as introduced in version 1.3 still remains as the highest available mode. DisplayPort 1.4 adds support for Display Stream Compression 1.2 (DSC), Forward Error Correction, HDR10 metadata defined in CTA-861.3, including static and dynamic metadata and the Rec. 2020 color space, for HDMI interoperability, and extends the maximum number of inline audio channels to 32.

=== Pharmacokinetics === The metabolism of 2C-EF has been studied in vitro. It undergoes demethylation at position 2 or 5, hydroxylation, and deamination, as well as acetylation and glucuronidation. Oxidative deamination, mediated mainly by monoamine oxidase (MAO) enzymes, is the main route of metabolism for 2C-EF.

==== Caesarean section ==== Women are less likely to start breastfeeding after caesarean delivery compared with vaginal delivery. Though the stress of a caesarean section (c-section) may impact let-down and flow, and though time for recovery immediately after surgery may be needed, women who give birth via c-section are still able to breastfeed. Generally, the benefits of breastfeeding outweigh the harms posed by pain medications following surgery. Mothers may need to experiment with different breastfeeding positions to avoid putting pressure on the incision.

Sources: en.wikipedia.org

Background from the literature

A variety of medical and psychological conditions have been misdiagnosed as anorexia nervosa; in some cases the correct diagnosis was not made for more than ten years. The distinction between binge purging anorexia, bulimia nervosa and Other Specified Feeding or Eating Disorders (OSFED) is often difficult for non-specialist clinicians. A main factor differentiating binge-purge anorexia from bulimia is the gap in physical weight. Patients with bulimia nervosa are ordinarily at a healthy weight, or slightly overweight. Patients with binge-purge anorexia are commonly underweight. Moreover, patients with the binge-purging subtype may be significantly underweight and typically do not binge-eat large amounts of food. In contrast, those with bulimia nervosa tend to binge large amounts of food. It is not unusual for patients with an eating disorder to "move through" various diagnoses as their behavior and beliefs change over time.

== Early political career == He transitioned into politics in 1977, when he served one term on the East Hartford Board of Education. He then served two terms on the East Hartford Town Council. In 1982, Larson was elected to the Connecticut State Senate from the 3rd district, based in East Hartford. He served six terms in that body, the last four as president pro tempore. In 1994, Larson left the state senate and sought the Democratic nomination for governor of Connecticut, losing to Bill Curry in the primary. After being defeated for governor, Larson entered private business for several years but was able to maintain his political credentials.

The strength of venom differs markedly between species and even more so between families, as measured by median lethal dose (LD50) in mice. Subcutaneous LD50 varies by over 140-fold within elapids and by more than 100-fold in vipers. The amount of venom produced also differs among species, with the Gaboon viper able to potentially deliver from 450 to 600 milligrams of venom in a single bite, the most of any snake. Opisthoglyphous colubrids have venom ranging from life-threatening (in the case of the boomslang) to barely noticeable (as in Tantilla).

=== Neoantigens === Neoantigens are those that are entirely absent from the normal human genome. As compared with nonmutated self-proteins, neoantigens are of relevance to tumor control, as the quality of the T cell pool that is available for these antigens is not affected by central T cell tolerance. Technology to systematically analyze T cell reactivity against neoantigens became available only recently. Neoantigens can be directly detected and quantified.

Sources: en.wikipedia.org

Further detail

In response to the proposed scheduling, the Texas Group increased production from 1985 estimates of 30,000 tablets a month to as many as 8,000 per day, potentially making two million ecstasy tablets in the months before MDMA was made illegal. By some estimates the Texas Group distributed 500,000 tablets per month in Dallas alone. According to one participant in an ethnographic study, the Texas Group produced more MDMA in eighteen months than all other distribution networks combined across their entire histories. By May 1985, MDMA use was widespread in California, Texas, southern Florida, and the northeastern United States. According to the DEA there was evidence of use in twenty-eight states and Canada. Urged by Senator Lloyd Bentsen, the DEA announced an emergency Schedule I classification of MDMA on 31 May 1985. The agency cited increased distribution in Texas, escalating street use, and new evidence of MDA (an analog of MDMA) neurotoxicity as reasons for the emergency measure. The ban took effect one month later on 1 July 1985 in the midst of Nancy Reagan's "Just Say No" campaign. As a result of several expert witnesses testifying that MDMA had an accepted medical usage, the administrative law judge presiding over the hearings recommended that MDMA be classified as a Schedule III substance. Despite this, DEA administrator John C. Lawn overruled and classified the drug as Schedule I.

While observing scouting photos of Cape Town, the filmmakers noticed a large three-walled external space that looked like an interior when filmed at night. A key sequence involving Ma-Ma and her gang firing rotary cannons across the atrium in their attempt to kill Judge Dredd required ten days of filming and eight different sets inside and outside the studio which were blended together with visual effects. Visual effects supervisor Jon Thum was unable to accompany a helicopter flight to obtain planned aerial shots of Johannesburg due to last-minute flight permissions; the resulting shots were non-specific and Thum had to pick out ones that could tell the story. Mantle had to develop new rigs to obtain close-up shots. Describing the aesthetic he aimed to achieve, he said: "I hope it will be more painterly. If we get it right, it will be a cross between Blade Runner and Clockwork Orange." Garland was a constant presence on the shoot; Urban turned to Garland for direction instead of Travis.

Drive to improve quality of patient care Need to contain burgeoning healthcare costs Improve accessibility and portability of patient records Better source data for epidemiological studies Before health records can be successfully communicated and stored there must be a fundamental agreement on the definition for each individual piece of information. Terminology solutions for describing such "concepts" currently include (but are not limited to) SNOMED CT, LOINC and the NPU. Key benefits conferred by the NPU terminology include:

Sources: en.wikipedia.org

Frequently asked questions

What is Semax made of?

It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.

Where did Semax originate?

It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.

Is Semax a licensed medicine?

It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.

What does the evidence base look like?

It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.

Network